EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Investigating Mammalian Formins with SMIFH2 Fifteen Years in: Novel Targets and Unexpected Biology

Metello Innocenti iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24109058 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Metello Innocenti. Beteiligte Einrichtung: Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy. Hauptthemen laut MEDLINE: Microfilament Proteins, Actins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union—NextGenerationEU, University of Milano Bicocca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mammalian formin family comprises fifteen multi-domain proteins that regulate actin dynamics and microtubules in vitro and in cells. Evolutionarily conserved formin homology (FH) 1 and 2 domains allow formins to locally modulate the cell cytoskeleton. Formins are involved in several developmental and homeostatic processes, as well as human diseases. However, functional redundancy has long hampered studies of individual formins with genetic loss-of-function approaches and prevents the rapid inhibition of formin activities in cells. The discovery of small molecule inhibitor of formin homology 2 domains (SMIFH2) in 2009 was a disruptive change that provided a powerful chemical tool to explore formins’ functions across biological scales. Here, I critically discuss the characterization of SMIFH2 as a pan-formin inhibitor, as well as growing evidence of unexpected off-target effects. By collating the literature and information hidden in public repositories, outstanding controversies and fundamental open questions about the substrates and mechanism of action of SMIFH2 emerge. Whenever possible, I propose explanations for these discrepancies and roadmaps to address the paramount open questions. Furthermore, I suggest that SMIFH2 be reclassified as a multi-target inhibitor for its appealing activities on proteins involved in pathological formin-dependent processes. Notwithstanding all drawbacks and limitations, SMIFH2 will continue to prove useful in studying formins in health and disease in the years to come.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Microfilament ProteinsActinsAnimalsHumansForminsCytoskeletonBiologyActin CytoskeletonMammals

Stichwörter der Autor:innen

HIV-1SMIFH2actincancercell migrationfilopodiaforminsinterferonmicrotubulesmyosin

Substanzen

ForminsMicrofilament ProteinsActins

Autor:innen und Institutionen

  • Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy.

ORCID-Profile: Metello Innocenti

Förderung

  • European Union—NextGenerationEU
  • University of Milano Bicocca

Zitieren

APA

Innocenti, M. (2023). Investigating Mammalian Formins with SMIFH2 Fifteen Years in: Novel Targets and Unexpected Biology. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24109058

Vancouver

Innocenti M. Investigating Mammalian Formins with SMIFH2 Fifteen Years in: Novel Targets and Unexpected Biology. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24109058

BibTeX
@article{Innocenti2023,
  author = {Innocenti, Metello},
  title = {Investigating Mammalian Formins with SMIFH2 Fifteen Years in: Novel Targets and Unexpected Biology},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24109058}
}
Kostenlos starten →